Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Results for uni: and multivariate logistic regression analysis of risk factors for eligibility to anti-osteoporosis medications. | Not eligible for AOM (N = 237) | Eligible for AOM (N = 69) | Univariate analysis OR [95%CI] | P-value | Multivariate analysis OR [95%CI] | P-value: 25 (OH) vitamin D level (ng/ml) | 26.3 ± 9.6 | 24.2 ± 10.2 | 0.98 [0.95 to 1.01] | 0.12 | |
Source: Results table. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
A Single-center, descriptive, cross-sectional study was conducted at Lille University Hospital.
Source: Methods.
The patients were prospectively referred between June 2019 and January 2025.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Bone Health and Anti-Osteoporotic Medication Eligibility in Postmenopausal Women Undergoing Bariatric Surgery: The Impact of Age and Modifiable Risk Factors
Cross-sectional study · Calcified Tissue International · 2026
Original publication title
Bone Health and Anti-Osteoporotic Medication Eligibility in Postmenopausal Women Undergoing Bariatric Surgery: The Impact of Age and Modifiable Risk Factors
© The Author(s) 2026
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Postoperative complications after metabolic and bariatric surgery (MBS) increase with age, yet data on bone health in older postmenopausal women remain limited. The 2022 European Calcified Tissue Society (ECTS) position statement recommend anti-osteoporotic medication (AOM) for patients with a T-score ≤ −2 and/or a fragility fracture within the past two years. This study evaluated the prevalence of AOM eligibility according to age (< 60 vs. ≥ 60 years) in postmenopausal women and identified associated risk factors.
Source: IntroductionAbstract: What methods does the paper describe?
We conducted a cross-sectional, observational, single-center study at Lille University Hospital including postmenopausal women referred for bone health evaluation before or after MBS. AOM eligibility was defined according to the 2022 ECTS criteria.
Source: Materials and MethodsAbstract: Results
Among 306 postmenopausal women, 173 were < 60 years (group 1) and 133 were ≥ 60 years (group 2). Overall, 69 patients (22.5%) were eligible for AOM, with a significantly higher prevalence in women ≥ 60 years (30.1% vs. 16.8%, p = 0.006). In multivariate analysis, independent predictors of AOM eligibility were age ≥ 60 years (OR = 2.34, 95% CI: 1.19 to 4.61), active smoking (OR = 2.98, 95% CI: 1.27 to 7.02), reduced appendicular lean mass index (ALMI < 5.5 kg/m2; OR = 3.72, 95% CI: 1.78 to 7.78), and elevated iPTH (OR = 1.15, 95% CI: 1.05 to 1.25 per 10 ng/mL increase).
Source: ResultsAbstract: Conclusion
Nearly one in five postmenopausal women undergoing MBS were eligible for AOM based on the ECTS position statement, with prevalence doubling after 60 years (OR = 2.34). Active smoking, secondary hyperparathyroidism, and low ALMI were key independent risk factors. These findings underscore the importance of systematic bone health assessment and early implementation of lifestyle interventions, alongside AOM, to reduce fracture risk in this vulnerable population.
Source: ConclusionAuthors’ abstract
Introduction
Postoperative complications after metabolic and bariatric surgery (MBS) increase with age, yet data on bone health in older postmenopausal women remain limited. The 2022 European Calcified Tissue Society (ECTS) position statement recommend anti-osteoporotic medication (AOM) for patients with a T-score ≤ −2 and/or a fragility fracture within the past two years. This study evaluated the prevalence of AOM eligibility according to age (< 60 vs. ≥ 60 years) in postmenopausal women and identified associated risk factors.
Materials and Methods
We conducted a cross-sectional, observational, single-center study at Lille University Hospital including postmenopausal women referred for bone health evaluation before or after MBS. AOM eligibility was defined according to the 2022 ECTS criteria.
Results
Among 306 postmenopausal women, 173 were < 60 years (group 1) and 133 were ≥ 60 years (group 2). Overall, 69 patients (22.5%) were eligible for AOM, with a significantly higher prevalence in women ≥ 60 years (30.1% vs. 16.8%, p = 0.006). In multivariate analysis, independent predictors of AOM eligibility were age ≥ 60 years (OR = 2.34, 95% CI: 1.19 to 4.61), active smoking (OR = 2.98, 95% CI: 1.27 to 7.02), reduced appendicular lean mass index (ALMI < 5.5 kg/m2; OR = 3.72, 95% CI: 1.78 to 7.78), and elevated iPTH (OR = 1.15, 95% CI: 1.05 to 1.25 per 10 ng/mL increase).
Conclusion
Nearly one in five postmenopausal women undergoing MBS were eligible for AOM based on the ECTS position statement, with prevalence doubling after 60 years (OR = 2.34). Active smoking, secondary hyperparathyroidism, and low ALMI were key independent risk factors. These findings underscore the importance of systematic bone health assessment and early implementation of lifestyle interventions, alongside AOM, to reduce fracture risk in this vulnerable population.
Publication and source details
Original title: Bone Health and Anti-Osteoporotic Medication Eligibility in Postmenopausal Women Undergoing Bariatric Surgery: The Impact of Age and Modifiable Risk Factors
Line Abdulghani; Hélène Verkindt; Laurine Cadart; Cécile Philippoteaux; Robert Caiazzo; Julien Paccou
Calcified Tissue International · 2026
© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Centre Hospitalier Universitaire de LilleOpen access funding provided by Centre Hospitalier Universitaire de Lille.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T00:15:31.722708+00:00
DOI: 10.1007/s00223-026-01484-z · PMC12858525